Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Finnair to fly to Guangzhou, China year-round as of winter 2019

Finnair extends its seasonal Guangzhou route to year-round operations and will operate between Helsinki and Guangzhou with two weekly frequencies during winter season 2019/2020. Finnair launched its Guangzhou route as a summer route in 2016, and as of this spring, will serve the route with its new Airbus A350 aircraft, adding both passenger and cargo capacity to the route.   “The extension of the operating season of our Guangzhou route is a logical next step in our Asian strategy”, says Christian Lesjak, SVP, Network and resource management, Finnair. “Travel between Finnair’s Chinese

Q-linea publish the Annual report for 2018

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), announced today that the Annual Report for the 2018 fiscal year has been published. The Annual Report is attached and can also be downloaded from the company’s website, www.qlinea.com      For more information, please contact:   Anders Lundin, CFO, Q-linea ABanders.lundin@qlinea.com+46 (0)70-600 15 20 This information is information that Q-linea AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 08:30 CET on April 17, 2019. About Q-

Acetium® lozenge for smoking intervention will shortly be distributed in Italy within Difar Consumer Care® product division

Press release                                            April 17th, 2019 at 09.30 local time (EEST) Biohit Oyj and Difar Distribuzione s.r.l have signed an agreement for the distribution of the Acetium® lozenge in Italy. CEO Semi Korpela, Biohit Oyj: “We are pleased to get the Acetium® lozenge available also in Italy. Acetium® lozenge for smoking intervention is one of Biohit’s numerous innovations resulting from the aggressive innovation and patenting strategy of the company. Acetium® lozenge is free from nicotine and side effects, and it offers a new and safe method for those

Dutch Deventer Hospital selects Sectra as its imaging IT vendor

Linköping, Sweden – April 17, 2019 – International medical imaging IT and cybersecurity company Sectra  (STO: SECT B) has signed a ten-year contract to install its solution for handling radiology images, Sectra PACS, across the radiology and nuclear medicine departments at Deventer Hospital in the Netherlands. The solution will support increased reading efficiency through its performance and comprehensive tool set, thereby improving patient outcomes.“It was important for us to select a dedicated and experienced vendor and with Sectra we’ll have a partner that will

Citycon Oyj to repurchase its own shares and to issue shares for the implementation of share based incentive programmes

CITYCON OYJ    Stock Exchange Release    17 April 2019 at 09:05 hrsBased on the decision of the Board of Directors on 16 April 2019, Citycon Oyj will repurchase and convey, always subject to a valid authorization granted by the Annual General Meeting of the company, in several separate transactions during 2019–2021, an aggregate maximum number of 171,300 of its own shares to implement payments of rewards earned under the company's share-based incentive programmes and agreed severance payments. This maximum number of shares corresponds to approximately 0.1 per cent of all the shares of the

Reminder: Invitation to presentation of Bonava’s interim report for the first quarter 2019

Bonava AB (publ) will publish its report for the first quarter 2019 on April 25 at 07:30 CET. The report will be presented to investors, analysts and the media at Bonava’s headquarters on April 25 at 10:00 CET.Venue: Bonava’s headquarters, Lindhagensgatan 72, Stockholm, Sweden. Date and time: April 25, 10:00–11:00 CET. Registration and coffee served from 9:30 CET. Program: Joachim Hallengren, CEO and Ann-Sofi Danielsson, CFO and Head of Investor Relations will present the report. The presentation will end with a Q&A. Registration: Register by e-mail at ir@bonava.com or by telephone

Alligator Bioscience AB (publ) Interim report January-March 2019

First patient dosed in Phase I clinical study of ATOR-1015Significant events January-March• First patient dosed in Phase I clinical study of ATOR-1015.• New preclinical data presented demonstrating strong anti-tumor effects for the 4-1BB antibody ATOR-1017.• Alligator Bioscience launched RUBY™, a novel concept in bispecific antibody formats. Events after the end of the period• Tumor-localizing properties of ATOR-1015 demonstrated by live imaging.• New preclinical data for ATOR-1144 demonstrates potential for activation of both the innate and the adaptive immune system as well

Interim Report January - March 2019

The first quarter entailed a positive start to the year: sales and profitability increased, both gross margin and cost control were strong, the market grew and Byggmax continued to take market share. Weather conditions were better than previous year, although not as favorable as in 2017.First quarter 2019: •Net sales increased by 7.5 percent to SEK 715.4 M (665.2)  •Gross margin increased to 33.4 percent (32.0) •EBITA margin excluding non recurring items increased to -10.9 percent (-14.6)

Ericsson and Swisscom in European commercial 5G first

· Issuing of commercial license enables long-term strategic partners to go live with 5G · Swisscom consumers to enjoy commercial 5G services in 54 initial cities and communities across Switzerland, enabled by Ericsson’s advanced 5G network features · Ericsson Spectrum Sharing will allow Swisscom to reach its goal of nationwide 5G coverage by end of 2019Ericsson (NASDAQ: ERIC) and Swisscom, the largest telecommunications service provider in Switzerland, have switched on the first large-scale commercial 5G network in Europe to support commercially available smartphones. The long-term

Notice to Annual General Meeting in Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ), Reg. No. 556734-5359, with registered office in Lund, summons to Annual General Meeting on Wednesday 22 Maj 2019 at 17.00 CEST at the auditorium next to the company’s premises, Scheelevägen 22, Lund, Sweden. Registration will begin at 16.30 CEST and will end when the meeting starts.Right to attend the Annual General Meeting To have the right to participate in the Annual General Meeting, the shareholder must be included in the shareholders’ register kept by Euroclear Sweden AB as of 16 May 2019 and notify the company of his or her participation at the Annual

Citycon Oyj’s Interim Report for 1 January – 31 March 2019: Stable overall development continued

Citycon Oyj   Interim Report   17 April 2019 at 09:00 hrs- Solid start to the year.- Growth in tenant sales and footfall.- Positive leasing spreads on renewals and re-lettings, country-wise in Sweden, Norway and Finland.- Administrative expenses declined by 12 % excluding one-off restructuring costs from organizational changes.- EPRA NAV increased compared to December 31, 2018 JANUARY—MARCH 2019 - Net rental income was EUR 53.6 million (Q1/2018: 53.3). Development project in Mölndal coming online increased net rental income by EUR 1.1 million, which was offset by planned

Nitro Games to receive funding from Business Finland

Nitro Games has received a positive decision from Business Finland to receive approximately 1.6M EUR of funding for a mobile esports project.Business Finland has approved the total cost estimate of 3,270,425 EUR for a mobile esports ecosystem project. This positive decision on funding from Business Finland is a maximum of 1,635,200 EUR (50% of the approved total costs for the project). The estimated project duration is 13 February 2019 – 30 September 2020. The project is closely tied to Nitro Games’ strategy and existing game portfolio of competitive multiplayer games. The project

Photocure ASA – Notice of the annual general meeting 9 May 2019

Oslo, 17 April 2019: Photocure ASA (OSE: PHO), calls for the annual general meeting of PHO to be held at Hoffsveien 4, 1st floor, 0275 Oslo, Norway on 9 May 2019 at 17:00 hours (CET).The notice convening the general meeting, including the agenda and the board's proposals to the matters to be dealt with, is enclosed with this notification and will be sent to all shareholders with known addresses. Relevant documents referred to in the notice are made available on www.photocure.com. For further information, please contact: Photocure CFO Erik DahlTel: +47 450 55 000, Email: ed@

Photocure ASA – Annual accounts 2018

Oslo, 17 April 2019: Photocure ASA (OSE: PHO), has published the annual accounts and annual report for the financial year 2018.The Company's annual accounts for the financial year 2018, including the financial statements and annual report for the financial year 2018, are together with the auditor's report attached to this notice. The documents are also available at the Company's website, www.photocure.com. For further information, please contact:Photocure CFO Erik DahlTel: +47 450 55 000, Email: ed@photocure.com About Photocure ASA  Photocure: The Bladder Cancer Company

NENT Group reveals documentary ‘Swedish Sin’ as next original series

· Five part documentary to premiere on Viaplay across the Nordic region on 17 May · NENT Group to premiere at least 20 original productions every year The documentary ‘Swedish Sin’ is the next original production from Nordic Entertainment Group (NENT Group). A five part series that recounts the rise and fall of notorious Swedish porn king Berth Milton Jr., ‘Swedish Sin’ will premiere across the Nordic region on 17 May exclusively on NENT Group’s Viaplay streaming service. Renowned and reviled in equal measure, Berth Milton Jr. was once one of Sweden’s wealthiest men. But at the

New study opens up new applications for SciBase’s product Nevisense

The Swiss Institute of Allergy and Asthma Research (SIAF) and SciBase announce today the publication of a breakthrough animal study within the area of skin barrier assessment. The paper, which is entitled ‘Direct assessment of skin epithelial barrier by electrical impedance spectroscopy’, was published online in the journal Allergy, European Journal of Allergy and Clinical Immunology. The study was performed in Davos by SIAF with support from SciBase, and the lead author for the publication was Prof. Cezmi A. Akdis, Director of SIAF. Building on work done within atopic dermatitis (AD) by

Interim report for 1 January – 31 March 2019

ALL COMPANIES IMPROVED EARNINGSFIRST QUARTER[1] · Net sales amounted to SEK 639.8 (716.1) million- Qliro Financial Services’ total operating income increased 26 percent- CDON Marketplace’ external merchant sales increased 36 percent while net sales decreased 31 percent in line with transformation- Nelly’s net sales increased 10 percent · Improved earnings in all companies- Qliro Financial Services’ operating profit before depreciation and amortization grew to SEK 14.0 (3.5) million- CDON Marketplace’ gross margin increased to 16.8 (10.5) percent and gross profit increased

Interim report January-March 2019

A QUARTER WITH A FOCUS ON THE FUTUREJanuary-Mars 2019 · Income amounted to SEK 1,480 million (1,485). · Operating profit amounted to SEK 18 million (52) · Profit for the period amounted to SEK 10 million (39) · Earnings per share after dilution amounted to SEK 0.44 (1.66) · The equity/assets ratio was 39.9 percent (42.7) · Cash flow from operating activities amounted to SEK -262 million (209) · Order bookings amounted to SEK 1,177 million (1,128) · The order backlog amounted to SEK 5,973 million (7,671)  Ola Serneke, CEO Serneke Group, comments: - The order

Sobi™ launches Liberate Life™, a vision of living life beyond haemophilia, on World Haemophilia Day

To mark World Haemophilia Day, Sobi™ is launching Liberate Life™, a vision of living life beyond haemophilia. In a series of long-term commitments, Sobi seeks to shape new standards, optimise treatment, build evidence, create sustainable access and provide community support in haemophilia care. As the first initiative in showcasing the Liberate Life vision, Sobi is reaching out to the broader haemophilia community across Europe through social media, encouraging and motivating people to expect more from life and reach for the many possibilities that advances in care have made possible. An

Restatement communication upon adoption of IFRS 16, Leases with full retrospective application

IFRS 16, Leases is mandatory for annual reporting periods starting on or after 1 January 2019. Medicover has adopted the standard from 1 January 2019. The standard applies new ways of accounting for leases in a unified approach and replaces the previous standard IAS 17, Leases. The standard impacts Medicover as a lessee and requires recognition in the statement of financial position of right-of-use assets and lease liabilities. This release provides information on the impact of the implementation of the standard on the Group’s IFRS financial statements for 2018 as restated for the full

Interim report January-March 2019

Quarter 1, 2019  · Incoming orders amounted to SEK 1,019.0m (781.7), which currency adjusted is an increase of 22.9 percent compared with the same period last year. · Net sales amounted to SEK 1,036.4m (785.8), which currency adjusted is an increase of 24.4 percent compared with the same period last year. · Adjusted operating profit was SEK 73.1m (62.9)*, giving an adjusted operating margin of 7.1 percent (8.0)*. · Operating profit was SEK 72.1m (62.9)*, giving an operating margin of 7.0 percent (8.0)*. · Net profit was SEK 46.2m (36.7)*. · Earnings per share were SEK 1.

Neste sets new strategic climate targets to reduce own and customers’ emissions

Neste Corporation Press Release 17 April, 2019 at 9:00 am (EET) As part of Neste’s renewed strategy , the company introduced two new ambitious climate targets: 1.To reduce customers’ greenhouse gas emissions with its renewable and circular solutions by at least 20 million tons CO2eq* annually by 2030 2.To reduce the carbon footprint of Neste’s production ahead of EU’s climate and energy targets. Customers’ greenhouse gas emissions reduction accelerated Over the past ten years, Neste

Broad support from shareholders for sale of shares

As previously announced by Zound Industries International AB, the company has initiated an exit process, which may lead to the sale of the shares of the Company or an initial public offering on Nasdaq Stockholm. The exit process is supported by the principal shareholders Zenith Venture Capital, Varenne, Telia Company and Time for Growth Secondary Fund (the "Principal Owners"), which jointly hold a majority of the shares in Zound Industries. The Principal Owners have now obtained support for the sale from shareholders which, together with Marshall Amplification, hold in excess of 90

There are no items matching the current filter
There are no more items matching the current filter
Back to top